Atlas Genetics completes final Series B tranche; GE Healthcare details amyloid imaging agent rollout plans;

> Atlas Genetics in the U.K. completed the final tranche of its Series B financing, in part to back European approval of its rapid point-of-care test for Chlamydia. Johnson & Johnson Development Corp., Novartis ($NVS) and others are among the participating investors. Release

> GE Healthcare ($GE) will be initially rolling out its Vizamyl imaging agent to help detect amyloid β buildup in the brain in 7 U.S. markets, beginning late in the 2014 second quarter. Release

> LabCorp's ($LH) revenue dipped during its 2014 first quarter, something the diagnostics giant blames on Medicare payment reductions and bad weather. Story

> Another day, another patent dispute in the life sciences world, this time between Illumina ($ILMN) and Ariosa Diagnostics. Story

> Ariosa Diagnostics has removed its IPO terms in an amendment filed with the SEC on April 29, a week after detailing those terms. Item

> Johnson & Johnson's ($JNJ) Ortho-Clinical Diagnostic unit outlined price guidance and terms on a $2.525 billion senior secured credit facility that will help fund its $4.15 acquisition by the Carlyle Group. Story

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.